Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380624193> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W4380624193 abstract "Background: Several studies have shown that high plasma concentrations of asymmetric dimethylarginine (ADMA), a known endogenous competitive inhibitor of endothelial nitric oxide synthase (eNOS), correlate with the severity of coronary artery disease (CAD), with worsening of cardiac ischemia/reperfusion (I/R) injury and coronary atherosclerosis. It is believed that it may be an important risk factor for myocardial infarction. ADMA, when in high concentrations, can determine a significant decrease in the synthesis and bioavailability of NO (Nitric oxide) and therefore alter the mechanisms of regulation of coronary vasodilation and vasomotor function of epicardial coronary arteries. Higher serum ADMA concentration is associated with worsening of post-ischemic remodeling since coronary angiogenesis, vasculogenesis, and collateral coronary growth are seriously impaired. In addition, there are reasons to believe that elevated plasma ADMA levels are related to the development of diseases affecting coronary microcirculation, such as ischemic non-obstructive coronary artery disease (INOCA). Methods: Methods: With the aim of providing the pharmacologist engaged in the design and discovery of new ADMA-lowering drugs with a complete examination of the subject, in this review, we discuss the most important studies related to the correlations between serum ADMA levels and cardiovascular diseases mentioned above. In addition, we critically discuss the main aspects of enzymology, synthesis, and metabolism of ADMA as a prerequisite for understanding the molecular mechanisms through which high concentrations of ADMA could contribute to promoting cardiovascular diseases. Results and Conclusion: ADMA represents a new target for pharmacological modulation of cardiovascular endothelial function and therefore, there is a possibility of using selective pharmacological ADMA lowering drugs in cardiovascular disease with endothelial dysfunction and high plasma ADMA levels." @default.
- W4380624193 created "2023-06-15" @default.
- W4380624193 creator A5004736442 @default.
- W4380624193 creator A5016965595 @default.
- W4380624193 creator A5026125076 @default.
- W4380624193 creator A5067994139 @default.
- W4380624193 date "2023-06-13" @default.
- W4380624193 modified "2023-09-27" @default.
- W4380624193 title "Asymmetric Dimethylarginine (ADMA) in Cardiovascular Disease, Cardiac Ischemia/reperfusion Injury, and Ischemic Non-obstructive Coronary Artery Disease: Biochemical and Pharmacological Implications" @default.
- W4380624193 doi "https://doi.org/10.2174/1570180820666230613163447" @default.
- W4380624193 hasPublicationYear "2023" @default.
- W4380624193 type Work @default.
- W4380624193 citedByCount "0" @default.
- W4380624193 crossrefType "journal-article" @default.
- W4380624193 hasAuthorship W4380624193A5004736442 @default.
- W4380624193 hasAuthorship W4380624193A5016965595 @default.
- W4380624193 hasAuthorship W4380624193A5026125076 @default.
- W4380624193 hasAuthorship W4380624193A5067994139 @default.
- W4380624193 hasConcept C120770815 @default.
- W4380624193 hasConcept C126322002 @default.
- W4380624193 hasConcept C164705383 @default.
- W4380624193 hasConcept C185592680 @default.
- W4380624193 hasConcept C2777468819 @default.
- W4380624193 hasConcept C2777622882 @default.
- W4380624193 hasConcept C2778213512 @default.
- W4380624193 hasConcept C2778326061 @default.
- W4380624193 hasConcept C2779877776 @default.
- W4380624193 hasConcept C2780972559 @default.
- W4380624193 hasConcept C500558357 @default.
- W4380624193 hasConcept C515207424 @default.
- W4380624193 hasConcept C519581460 @default.
- W4380624193 hasConcept C541997718 @default.
- W4380624193 hasConcept C55493867 @default.
- W4380624193 hasConcept C71924100 @default.
- W4380624193 hasConceptScore W4380624193C120770815 @default.
- W4380624193 hasConceptScore W4380624193C126322002 @default.
- W4380624193 hasConceptScore W4380624193C164705383 @default.
- W4380624193 hasConceptScore W4380624193C185592680 @default.
- W4380624193 hasConceptScore W4380624193C2777468819 @default.
- W4380624193 hasConceptScore W4380624193C2777622882 @default.
- W4380624193 hasConceptScore W4380624193C2778213512 @default.
- W4380624193 hasConceptScore W4380624193C2778326061 @default.
- W4380624193 hasConceptScore W4380624193C2779877776 @default.
- W4380624193 hasConceptScore W4380624193C2780972559 @default.
- W4380624193 hasConceptScore W4380624193C500558357 @default.
- W4380624193 hasConceptScore W4380624193C515207424 @default.
- W4380624193 hasConceptScore W4380624193C519581460 @default.
- W4380624193 hasConceptScore W4380624193C541997718 @default.
- W4380624193 hasConceptScore W4380624193C55493867 @default.
- W4380624193 hasConceptScore W4380624193C71924100 @default.
- W4380624193 hasLocation W43806241931 @default.
- W4380624193 hasOpenAccess W4380624193 @default.
- W4380624193 hasPrimaryLocation W43806241931 @default.
- W4380624193 hasRelatedWork W2061561342 @default.
- W4380624193 hasRelatedWork W2337772816 @default.
- W4380624193 hasRelatedWork W2417414779 @default.
- W4380624193 hasRelatedWork W2790353319 @default.
- W4380624193 hasRelatedWork W2792670065 @default.
- W4380624193 hasRelatedWork W2890630804 @default.
- W4380624193 hasRelatedWork W2896893594 @default.
- W4380624193 hasRelatedWork W2967733282 @default.
- W4380624193 hasRelatedWork W4318928764 @default.
- W4380624193 hasRelatedWork W1927863502 @default.
- W4380624193 hasVolume "20" @default.
- W4380624193 isParatext "false" @default.
- W4380624193 isRetracted "false" @default.
- W4380624193 workType "article" @default.